title: Early versus deferred hormone therapy.
abstract: Although hormone therapy is widely used in the management of prostate cancer, the optimal timing of its initiation remains a matter of debate. Immediate hormone treatment has been compared with deferred treatment in randomized studies conducted by the Veterans Administration Cooperative Urological Research Group, the South Sweden Prostate Cancer Study Group and the Medical Research Council. Despite criticism of the design of these studies, the results indicate that early treatment may be associated with advantages in time to progression and survival. It is anticipated that ongoing studies, such as the European Organization for Research and Treatment of Cancer protocols 30846 and 30891, will provide further information on the optimal timing of endocrine treatment. Prognostic and quality of life factors also have an impact on the treatment decision. On the basis of available evidence, early hormone therapy is recommended for younger men with poorly differentiated tumours or advanced disease and for those who are seen infrequently by their physician. Deferred treatment using a strategy of watchful waiting is probably the best option for older men with well differentiated, low volume prostate cancer.
authors.affiliation: Department of Urology, Royal Hallamshire Hospital, Sheffield, UK. john.anderson@csuh-tr.trent.nhs.uk
authors.forename: J B
authors.initials: JB
authors.lastname: Anderson
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate
chemical_list: D018931:Antineoplastic Agents, Hormonal